Alkem Laboratories has informed that the Company and Biosergen AB (‘Biosergen’), have entered into a co-development and license agreement for the development and commercialization of Biosergen’s novel polyene macrolide antifungal product BSG005 for the treatment of severe invasive fungal disease. A press release in this regard is enclosed.
The above information is a part of company’s filings submitted to BSE.